Free Trial
NASDAQ:IDYA

IDEAYA Biosciences Q3 2024 Earnings Report

IDEAYA Biosciences logo
$19.07 +0.25 (+1.33%)
Closing price 04/24/2025 04:00 PM Eastern
Extended Trading
$19.75 +0.68 (+3.57%)
As of 09:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEAYA Biosciences EPS Results

Actual EPS
-$0.60
Consensus EPS
-$0.63
Beat/Miss
Beat by +$0.03
One Year Ago EPS
-$0.46

IDEAYA Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
$4.27 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

IDEAYA Biosciences Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Conference Call Date
Monday, November 4, 2024
Conference Call Time
6:00AM ET

Upcoming Earnings

IDEAYA Biosciences' Q1 2025 earnings is scheduled for Tuesday, May 6, 2025, with a conference call scheduled on Wednesday, May 7, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

IDEAYA Biosciences Earnings Headlines

Feds Just Admitted It—They Can Take Your Cash
Here’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousands of smart, forward-thinking individuals are making the move—out of the system and into real, untouchable assets. Because once your funds are frozen, it’s too late.
See More IDEAYA Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like IDEAYA Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IDEAYA Biosciences and other key companies, straight to your email.

About IDEAYA Biosciences

IDEAYA Biosciences (NASDAQ:IDYA), a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

View IDEAYA Biosciences Profile

More Earnings Resources from MarketBeat